Elijah Trefts

Elijah Trefts

Auto-generated profile, based on publicly available information

Elijah Trefts

The Salk Institute for Biological Studies, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Molecular Cell
Verified
Journal Article
Open access
ETElijah Trefts
Elijah Trefts
RSReuben J. Shaw
Reuben J. Shaw
The evolution of AMPK and its homologues enabled exquisite responsivity and control of cellular energetic homeostasis. Recent work has been critical in establishing the mechanisms that determine AMPK activity, novel targets of AMPK action, and the distribution of AMPK-mediated control networks across the cellular landscape. The role of AMPK as a hub of metabolic control has led to intense interest in pharmacologic activation as a therapeutic avenue for a number of disease states including obesity, diabetes, and cancer. As such, critical work on the compartmentalization of AMPK, its downstream targets, and the systems it influences have progressed in recent years. The variegated distribution of AMPK-mediated control of metabolic homeostasis has revealed key insights on AMPK in normal biology and future directions for AMPK-based therapeutic strategies.

21 April 2023 in Science
Verified
Journal Article
Closed access
NMNazma Malik
Nazma Malik
BFBibiana Ferreira
Bibiana Ferreira
PHPablo E. Hollstein
Pablo E. Hollstein
SCStephanie D. Curtis
Stephanie D. Curtis
ETElijah Trefts
Elijah Trefts
RSReuben J. Shaw
Reuben J. Shaw
Cells respond to mitochondrial poisons with rapid activation of the adenosine monophosphate–activated protein kinase (AMPK), causing acute metabolic changes through phosphorylation and prolonged adaptation of metabolism through transcriptional effects. Transcription factor EB (TFEB) is a major effector of AMPK that increases expression of lysosome genes in response to energetic stress, but how AMPK activates TFEB remains unresolved. We demonstrate that AMPK directly phosphorylates five conserved serine residues in folliculin-interacting protein 1 (FNIP1), suppressing the function of the folliculin (FLCN)–FNIP1 complex. FNIP1 phosphorylation is required for AMPK to induce nuclear translocation of TFEB and TFEB-dependent increases of peroxisome proliferator–activated receptor gamma coactivator 1-alpha (PGC1α) and estrogen-related receptor alpha (ERRα) messenger RNAs. Thus, mitochondrial damage triggers AMPK-FNIP1–dependent nuclear translocation of TFEB, inducing sequential waves of lysosomal and mitochondrial biogenesis.

30 June 2023 in Science
Verified
Journal Article
Closed access
TZTao Zhang
Tao Zhang
DXDaichao Xu
Daichao Xu
ETElijah Trefts
Elijah Trefts
MLMingming Lv
Mingming Lv
HIHiroyuki Inuzuka
Hiroyuki Inuzuka
WWWenyi Wei
Wenyi Wei
Adenosine monophosphate–activated protein kinase (AMPK) activity is stimulated to promote metabolic adaptation upon energy stress. However, sustained metabolic stress may cause cell death. The mechanisms by which AMPK dictates cell death are not fully understood. We report that metabolic stress promoted receptor-interacting protein kinase 1 (RIPK1) activation mediated by TRAIL receptors, whereas AMPK inhibited RIPK1 by phosphorylation at Ser 415 to suppress energy stress–induced cell death. Inhibiting pS415-RIPK1 by Ampk deficiency or RIPK1 S415A mutation promoted RIPK1 activation. Furthermore, genetic inactivation of RIPK1 protected against ischemic injury in myeloid Ampkα1 -deficient mice. Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a previously unappreciated role for the AMPK-RIPK1 axis in integrating metabolism, cell death, and inflammation.

17 March 2023 in Science Advances
Verified
Journal Article
Closed access
LELillian J. Eichner
Lillian J. Eichner
SCStephanie D. Curtis
Stephanie D. Curtis
SBSonja N. Brun
Sonja N. Brun
CMCaroline K. McGuire
Caroline K. McGuire
IGIrena Gushterova
Irena Gushterova
RSReuben J. Shaw
Reuben J. Shaw
HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown. We identified a critical role for HDAC3 in Kras -mutant lung cancer. Using genetically engineered mouse models (GEMMs), we found that HDAC3 is required for lung tumor growth in vivo. HDAC3 was found to direct and enhance the transcription effects of the lung cancer lineage transcription factor NKX2-1 to mediate expression of a common set of target genes. We identified FGFR1 as a critical previously unidentified target of HDAC3. Leveraging this, we identified that an HDAC3-dependent transcriptional cassette becomes hyperactivated as Kras/LKB1 -mutant cells develop resistance to the MEK inhibitor trametinib, and this can be reversed by treatment with the HDAC1/HDAC3 inhibitor entinostat. We found that the combination of entinostat plus trametinib treatment elicits therapeutic benefit in the Kras/LKB1 GEMM.

15 October 2021 in Science Advances
Verified
Journal Article
Open access
ELEsther W. Lim
Esther W. Lim
MHMichal K. Handzlik
Michal K. Handzlik
ETElijah Trefts
Elijah Trefts
JGJivani M. Gengatharan
Jivani M. Gengatharan
CPCarlos M. Pondevida
Carlos M. Pondevida
CMChristian M. Metallo
Christian M. Metallo
Alanine accumulation in Polg D257A mice links mitochondrial defects to 1-deoxysphingolipids and peripheral neuropathy.